Seven-year follow-up data of a multicenter, randomized phase 2 study evaluating the treatment of melanoma brain metastases shows ipilimumab plus nivolumab is an effective long-term care option. First ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback